HPV genotyping in biopsies of HSIL and invasive cervical cancers in women living with HIV: A cohort- and a nested -case control study.

Autor: Gilles C; Department of Obstetrics and Gynecology, Saint Pierre University Hospital Brussels, Université Libre de Bruxelles (ULB), Free University of Brussels (ULB-VUB), 322 Rue Haute, 1000 Brussels, Belgium. Electronic address: christine.gilles@stpierre-bru.be., Rozenberg S; Department of Obstetrics and Gynecology, Saint Pierre University Hospital Brussels, Université Libre de Bruxelles (ULB), Free University of Brussels (ULB-VUB), 322 Rue Haute, 1000 Brussels, Belgium., Buxant F; Gynecology Unit, Iris South Hospital-Free University of Brussels, Brussels, Belgium., Manigart Y; Department of Obstetrics and Gynecology, Saint Pierre University Hospital Brussels, Université Libre de Bruxelles (ULB), Free University of Brussels (ULB-VUB), 322 Rue Haute, 1000 Brussels, Belgium., de Wind R; Department of Pathology, Institute Jules Bordet, Université Libre de Bruxelles (ULB), Brussels, Belgium., Houte KV; Department of Pathology CHU Brugmann, Free University of Brussels, Brussels, Belgium., Vandenbroeck D; Laboratory of Molecular Pathology AML, Antwerp, Belgium., Delforge M; Infectious Disease Department, Saint-Pierre University Hospital Brussels, Université Libre de Bruxelles (ULB), Brussels, Belgium., Konopnicki D; Infectious Disease Department, Saint-Pierre University Hospital Brussels, Université Libre de Bruxelles (ULB), Brussels, Belgium.
Jazyk: angličtina
Zdroj: Vaccine [Vaccine] 2022 Nov 28; Vol. 40 (50), pp. 7230-7237. Date of Electronic Publication: 2022 Oct 31.
DOI: 10.1016/j.vaccine.2022.10.029
Abstrakt: Objective: To characterize HPV genotype distribution in HSIL and ICC- biopsies, of WLWH, in Europe, as compared to HIV-negative women.
Design: Cohort- and nested -case control study.
Method: We characterized HPV genotype distribution by performing PCR on HSIL and ICC biopsies from WLWH (n = 170); 85 cases were compared to 85 HIV-negative matched controls. The proportion of patients that might be protected by HPV vaccines was estimated.
Results: Among WLWH (median age 36 years-old, median duration of HIV infection 70,5 months, 79% under cART): the most frequently detected HPV were HPV16 (30%), HPV35 (16%), HPV58 (14,7%), HPV31 (13,5%), and HPV52 (11,7%). HPV16 was less frequently found in WLWH, originating from Central Africa (20,5%) compared to other African regions (35,5%) (p = 0,05) or world regions (38,8%) (p = 0,007). Multiple versus single high-risk HPV infections were associated with younger age (≤35 years)(odds ratio (OR) 2,65 (95%IC: 1,3-5,2,p = 0,002), lymphocyte CD4 count < 350 cells / µL (OR 2,7 (95%IC: 2-8,5; p = 0,005), use of cART for < 18 month OR 2,2 (95%IC: 1,1-4,5),p = 0,04) or a cumulative time with undetectable HIV viral load of less than 12 months (OR 4,2 (95%IC: 2-8.5,p = 0,001). HPV 31, 33 and 35 were more frequently detected in samples from WLWH than in HIV-negative controls (p < 0,05). The 9-valent vaccine would increase HPV protection, in HIV-positive and negative women (p < 0,001).
Conclusion: WLWH are more frequently infected with high-risk HPV other than 16 and 18 than HIV-negative ones. The use of 9-valent vaccine may prevent HSIL or ICC in up to 85% of the women. Adding HPV 35 to the HPV vaccine panel, might improve vaccine effectiveness in WLWH.
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2022 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: